+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

All Ages
All Genders
ID06807190

Real-World Safety and Clinical Monitoring of Awiqli in People with Diabetes Mellitus in Japan Over One Year

Led by Novo Nordisk A/S · Updated on 2026-08-27

630

Participants Needed

116

Research Sites

26 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and clinical effects of Awiqli in people with diabetes mellitus in Japan during routine medical care. This observational study aims to collect real-world data on the use of Awiqli over a one-year period. The study focuses on participants with any type of diabetes who are prescribed Awiqli independently of the study. Participants will receive commercially available Awiqli as directed by their treating doctors according to standard clinical practice. There is no experimental treatment assignment as this is a non-interventional study. The study observes the use of Awiqli over 52 weeks without altering usual care. During the study, participants will be monitored for adverse reactions and events, serious adverse events, and changes in diabetes-related clinical parameters including HbA1c, fasting plasma glucose, and diabetes therapy-related quality of life. Data will be collected from baseline through week 52. The total participation time lasts about one year.

CONDITIONS

Brief Title

General Use-results Surveillance With Awiqli in Patients With Diabetes Mellitus

Research Team

N

Novo Nordisk

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here